Leap Investments’s Anika Therapeutics ANIK Stock Holding History

Leap Investments’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-4,800	Closed	-$263K	–	420
2019 Q3	$263K	Buy	+4,800	New	+$246K	0.13%	256

Other funds holding ANIK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Leap Investments's ANIK Position: Q4 2019 in Review

Leap Investments sold out of Anika Therapeutics (ANIK) in Q4 2019, closing a stake of 4,800 shares — an estimated $263K sold.

Leap Investments first reported a position in ANIK in Q3 2019 and held it in 1 quarter. The position peaked at $263K in Q3 2019. 191 funds tracked by Wall St. Rank hold ANIK as of Q4 2019.

Leap Investments reported no remaining Anika Therapeutics position as of Q4 2019 after selling out during the quarter.
Leap Investments sold 4,800 Anika Therapeutics shares in Q4 2019, an estimated $263K.
Leap Investments first reported a position in Anika Therapeutics in Q3 2019 and held it in 1 quarter.
Leap Investments's Anika Therapeutics position peaked at $263K in Q3 2019.
191 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2019.

Based on Leap Investments's 13F filing for Q4 2019, filed 14 Feb 2020.